Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.25

+1.9%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.08B
EPS-0.5300
P/E Ratio-9.91
Earnings Date08/06/2026

svra

Total Current Liabilities

Last Annual Value

20.40M

3-Year CAGR

51%

5-Year CAGR

20%

10-Year CAGR

-1%

Savara Inc.

Savara Inc. Competitors Analysis of Total Current Liabilities

SVRA · NASDAQ
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
20.40M
24.4%6.8%19.4% 
116.97M
49.1%39.1%35.9%
111.54M
1.1%19.6%30.4%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
11.91M
31.8%43.3%21.3%
28.95M
24.3%N/AN/A
21.68M
-22.1%-11.8%N/A
18.09M
5.7%38.0%N/A
37.02M
-16.4%9.4%21.9%
PROK logo
ProKidney Corp.
NASDAQ:PROK
30.74M
7.1%20.1%N/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.25, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.25